RADLY Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of 4.1% compared to Raia Drogasil SA's net margin of --. Raia Drogasil SA's return on equity of 20.46% beat CEL-SCI Corp.'s return on equity of -230.36%.

Raia Drogasil SA has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 563.03%. Given that CEL-SCI Corp. has higher upside potential than Raia Drogasil SA, analysts believe CEL-SCI Corp. is more attractive than Raia Drogasil SA.

Raia Drogasil SA has a beta of -0.065, which suggesting that the stock is 106.47% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.183%.

Raia Drogasil SA has a quarterly dividend of $0.03 per share corresponding to a yield of 0.61%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Raia Drogasil SA pays 34.22% of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend. Raia Drogasil SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Raia Drogasil SA quarterly revenues are $2.1B, which are larger than CEL-SCI Corp. quarterly revenues of --. Raia Drogasil SA's net income of $84.7M is higher than CEL-SCI Corp.'s net income of -$6.1M. Notably, Raia Drogasil SA's price-to-earnings ratio is 35.48x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raia Drogasil SA is 1.11x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Hypera SA has a net margin of 4.1% compared to Raia Drogasil SA's net margin of 20.38%. Raia Drogasil SA's return on equity of 20.46% beat Hypera SA's return on equity of 6.9%.

Raia Drogasil SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Hypera SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Raia Drogasil SA has higher upside potential than Hypera SA, analysts believe Raia Drogasil SA is more attractive than Hypera SA.

Raia Drogasil SA has a beta of -0.065, which suggesting that the stock is 106.47% less volatile than S&P 500. In comparison Hypera SA has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.585%.

Raia Drogasil SA has a quarterly dividend of $0.03 per share corresponding to a yield of 0.61%. Hypera SA offers a yield of 2.17% to investors and pays a quarterly dividend of $0.05 per share. Raia Drogasil SA pays 34.22% of its earnings as a dividend. Hypera SA pays out 36.44% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Raia Drogasil SA quarterly revenues are $2.1B, which are larger than Hypera SA quarterly revenues of $408.8M. Raia Drogasil SA's net income of $84.7M is higher than Hypera SA's net income of $83.3M. Notably, Raia Drogasil SA's price-to-earnings ratio is 35.48x while Hypera SA's PE ratio is 21.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raia Drogasil SA is 1.11x versus 2.61x for Hypera SA. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of 4.1% compared to Raia Drogasil SA's net margin of -953.4%. Raia Drogasil SA's return on equity of 20.46% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Raia Drogasil SA has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1186.95%. Given that IGC Pharma, Inc. has higher upside potential than Raia Drogasil SA, analysts believe IGC Pharma, Inc. is more attractive than Raia Drogasil SA.

Raia Drogasil SA has a beta of -0.065, which suggesting that the stock is 106.47% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.78%.

Raia Drogasil SA has a quarterly dividend of $0.03 per share corresponding to a yield of 0.61%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Raia Drogasil SA pays 34.22% of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend. Raia Drogasil SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Raia Drogasil SA quarterly revenues are $2.1B, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Raia Drogasil SA's net income of $84.7M is higher than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Raia Drogasil SA's price-to-earnings ratio is 35.48x while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raia Drogasil SA is 1.11x versus 22.60x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of 4.1% compared to Raia Drogasil SA's net margin of -255.85%. Raia Drogasil SA's return on equity of 20.46% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Raia Drogasil SA has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.49%. Given that NovaBay Pharmaceuticals, Inc. has higher upside potential than Raia Drogasil SA, analysts believe NovaBay Pharmaceuticals, Inc. is more attractive than Raia Drogasil SA.

Raia Drogasil SA has a beta of -0.065, which suggesting that the stock is 106.47% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Raia Drogasil SA has a quarterly dividend of $0.03 per share corresponding to a yield of 0.61%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Raia Drogasil SA pays 34.22% of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Raia Drogasil SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Raia Drogasil SA quarterly revenues are $2.1B, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Raia Drogasil SA's net income of $84.7M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Raia Drogasil SA's price-to-earnings ratio is 35.48x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raia Drogasil SA is 1.11x versus 10.65x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.